Literature DB >> 1967929

Amplification of the c-erb B-2 oncogene and prognosis of breast adenocarcinoma.

N H Heintz1, K O Leslie, L A Rogers, P L Howard.   

Abstract

Fifty patients with typical infiltrating ductal adenocarcinoma of the breast were studied for amplification of the c-erb B-2 (neu/HER-2) oncogene within the tumor DNA. Amplification, ranging from 4 to greater than 50 copies per cell, was observed in 17 (34%) of the samples. The presence of c-erb B-2 gene amplification was not significantly correlated with patient survival, metastases, recurrence, or overall histologic grade. However, amplification was significantly associated with increased mitotic activity. Also, amplification of c-erb B-2 showed a significantly negative association with both progesterone and estrogen receptor presence. Progesterone receptor presence correlated significantly with survival.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1967929

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  15 in total

1.  Relationship between c-erbB-2 immunoreactivity and thymidine labelling index in breast carcinoma in situ.

Authors:  D M Barnes; J S Meyer; J G Gonzalez; W J Gullick; R R Millis
Journal:  Breast Cancer Res Treat       Date:  1991-03       Impact factor: 4.872

2.  Biological indices in the assessment of breast cancer.

Authors:  A S Leong; A K Lee
Journal:  Clin Mol Pathol       Date:  1995-10

3.  Lack of c-erbB-2 oncoprotein expression in male breast carcinoma.

Authors:  S B Fox; C A Day; S Rogers
Journal:  J Clin Pathol       Date:  1991-11       Impact factor: 3.411

4.  c-erbB-2 expression in different histological types of invasive breast carcinoma.

Authors:  S Soomro; S Shousha; P Taylor; H M Shepard; M Feldmann
Journal:  J Clin Pathol       Date:  1991-03       Impact factor: 3.411

5.  Her-2/neu expression as a predictive factor for response to anthracycline-based chemotherapy in a mexican population of locally advanced breast cancer patients.

Authors:  David Muñoz-Gonzalez; Isabel Zeichner-Gancz; Myrna Candelaria; Maria Teresa Ramirez-Ugalde; Manuel Perez-Sanchez; Guadalupe Cervantes-Vazquez; David Cantu-de Leon; Arcelia Mora-Tizcareño; Julio Leonor-Ortíz
Journal:  Med Oncol       Date:  2005       Impact factor: 3.064

6.  ErbB-2 oncoprotein overexpression in breast carcinoma: inverse correlation with biochemically- and immunohistochemically-determined hormone receptors.

Authors:  A A Keshgegian
Journal:  Breast Cancer Res Treat       Date:  1995-08       Impact factor: 4.872

7.  Prognostic value of c-erbB-2 expression in uterine cervical carcinoma.

Authors:  R J Hale; C H Buckley; H Fox; J Williams
Journal:  J Clin Pathol       Date:  1992-07       Impact factor: 3.411

8.  Cancer biomarker HER-2/neu in breast cancer in Indian women.

Authors:  Rajeev Singhai; Amit V Patil; Vinayak W Patil
Journal:  Breast Cancer (Dove Med Press)       Date:  2011-03-29

9.  The prognostic value of c-erbB2 in primary breast carcinomas: a study on 942 cases.

Authors:  N Quénel; J Wafflart; F Bonichon; I de Mascarel; M Trojani; M Durand; A Avril; J M Coindre
Journal:  Breast Cancer Res Treat       Date:  1995-09       Impact factor: 4.872

10.  Immunohistochemical investigation and northern blot analysis of c-erB-2 expression in normal, premalignant and malignant tissues of the corpus and cervix uteri.

Authors:  C Brumm; A Rivière; C Wilckens; T Löning
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1990
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.